MCID: SCR001
MIFTS: 41

Secretory Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Secretory Meningioma

MalaCards integrated aliases for Secretory Meningioma:

Name: Secretory Meningioma 12 54 15 17 71
Meningioma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4588
MeSH 43 D008579
NCIt 49 C4718
SNOMED-CT 67 253081009
UMLS 71 C0025286 C1384406

Summaries for Secretory Meningioma

MalaCards based summary : Secretory Meningioma, also known as meningioma, is related to meningioma, radiation-induced and signet ring cell adenocarcinoma. An important gene associated with Secretory Meningioma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and pituitary, and related phenotype is Increased proliferation.

Related Diseases for Secretory Meningioma

Diseases related to Secretory Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 320, show less)
# Related Disease Score Top Affiliating Genes
1 meningioma, radiation-induced 30.4 VIM SMARCB1 NF2 MUC1
2 signet ring cell adenocarcinoma 29.9 MUC1 KRT7 CEACAM5
3 spinal meningioma 29.9 TRAF7 SMARCE1 SMARCB1 NF2
4 meningothelial meningioma 29.5 TRAF7 SMARCE1 SERPINA3 NF2
5 meningioma, familial 29.1 TRAF7 SMARCE1 SMARCB1 SERPINA3 NF2 KLF4
6 lymphoplasmacyte-rich meningioma 10.7
7 perineurioma 10.5 VIM MUC1
8 papillary tumor of the pineal region 10.5 VIM MUC1
9 endometrial mucinous adenocarcinoma 10.5 VIM MUC1
10 scrotum paget's disease 10.5 MUC1 KRT7
11 gallbladder signet ring cell adenocarcinoma 10.5 MUC1 KRT7
12 cutaneous leiomyosarcoma 10.5 VIM MUC1
13 middle ear adenoma 10.4 MUC1 KRT7
14 reticulum cell sarcoma 10.4 VIM MUC1
15 extraskeletal ewing sarcoma 10.4 VIM MUC1
16 desmoplastic small round cell tumor 10.4 VIM MUC1
17 pericardial mesothelioma 10.4 VIM MUC1
18 benign metastasizing leiomyoma 10.4 VIM KRT7
19 glandular cystitis 10.4 MUC1 KRT7
20 clear cell ependymoma 10.4 VIM MUC1
21 cystadenofibroma 10.4 MUC1 KRT7
22 ossifying fibromyxoid tumor 10.4 VIM MUC1
23 solid adenocarcinoma with mucin production 10.4 MUC1 KRT7
24 polymorphous low-grade adenocarcinoma 10.4 VIM MUC1
25 biphasic synovial sarcoma 10.4 VIM MUC1
26 mucinous tubular and spindle renal cell carcinoma 10.4 MUC1 KRT7
27 brain edema 10.4
28 endosalpingiosis 10.4 MUC1 KRT7
29 ovarian serous cystadenofibroma 10.4 MUC1 KRT7
30 mixed fibrolamellar hepatocellular carcinoma 10.4 MUC1 KRT7
31 dendritic cell tumor 10.4 VIM MUC1
32 intravascular papillary endothelial hyperplasia 10.4 VIM SERPINA3
33 renal pelvis carcinoma 10.4 KRT7 CEACAM7
34 malignant peritoneal mesothelioma 10.4 NF2 MUC1
35 congenital epulis 10.4 VIM SERPINA3
36 nephrogenic adenoma 10.4 MUC1 KRT7
37 epulis 10.4 VIM SERPINA3
38 syringocystadenoma papilliferum 10.4 SERPINA3 MUC1
39 granulosa cell tumor of the ovary 10.3 VIM KRT7
40 multicentric reticulohistiocytosis 10.3 VIM SERPINA3
41 adenomyoma 10.3 MUC1 KRT7
42 odontogenic myxoma 10.3 VIM SERPINA3
43 gastric squamous cell carcinoma 10.3 SERPINA3 KRT7
44 vulvar eccrine porocarcinoma 10.3 MUC1 CEACAM5
45 lipid-rich breast carcinoma 10.3 MUC1 CEACAM5
46 astroblastoma 10.3 VIM MUC1
47 embryonal sarcoma 10.3 VIM SERPINA3
48 osteofibrous dysplasia 10.3 VIM MUC1
49 sclerosing hemangioma 10.3 MUC1 KRT7
50 pediatric meningioma 10.3 TRAF7 NF2
51 brain meningioma 10.3 TRAF7 NF2
52 parachordoma 10.3 VIM MUC1 KRT7
53 leukoplakia of penis 10.3 KRT7 CEACAM5
54 intraventricular meningioma 10.3 TRAF7 NF2
55 bile duct adenoma 10.3 VIM MUC1 KRT7
56 spiradenoma 10.3 VIM MUC1 KRT7
57 olfactory groove meningioma 10.3 TRAF7 NF2
58 monophasic synovial sarcoma 10.3 VIM MUC1 KRT7
59 psammomatous meningioma 10.3 TRAF7 NF2
60 urethral villous adenoma 10.3 KRT7 CEACAM5
61 metanephric adenoma 10.3 VIM MUC1 KRT7
62 adenofibroma 10.3 VIM MUC1 KRT7
63 papillary cystadenocarcinoma 10.3 SERPINA3 KRT7
64 meninges hemangiopericytoma 10.3 TRAF7 NF2
65 ureter adenocarcinoma 10.3 KRT7 CEACAM5
66 anterior cranial fossa meningioma 10.3 TRAF7 NF2
67 esophageal adenoid cystic carcinoma 10.3 VIM CEACAM5
68 malignant acrospiroma 10.3 KRT7 CEACAM5
69 sertoli cell tumor 10.3 VIM MUC1 KRT7
70 mucinous adenofibroma 10.3 KRT7 CEACAM5
71 tumor of exocrine pancreas 10.3 MUC1 CEACAM5
72 cutaneous mucoepidermoid carcinoma 10.3 KRT7 CEACAM5
73 vulva adenocarcinoma 10.3 KRT7 CEACAM5
74 vulval paget's disease 10.3 KRT7 CEACAM5
75 cystitis cystica 10.3 KRT7 CEACAM5
76 pancreatic serous cystadenocarcinoma 10.3 KRT7 CEACAM5
77 spindle cell carcinoma 10.3 VIM MUC1 KRT7
78 eccrine adenocarcinoma 10.3 KRT7 CEACAM5
79 cavernous hemangioma 10.3 VIM MUC1 KRT7
80 renal pelvis adenocarcinoma 10.3 KRT7 CEACAM5
81 external ear carcinoma 10.3 KRT7 CEACAM5
82 anal paget's disease 10.3 KRT7 CEACAM5
83 vaginal tubulovillous adenoma 10.2 KRT7 CEACAM5
84 endometrial adenocarcinoma 10.2 VIM MUC1 KRT7
85 female urethral cancer 10.2 KRT7 CEACAM5
86 vulvar apocrine adenocarcinoma 10.2 KRT7 CEACAM5
87 mucinous ovarian cystadenoma 10.2 KRT7 CEACAM5
88 ovarian cystadenoma 10.2 KRT7 CEACAM5
89 rectosigmoid junction neoplasm 10.2 KRT7 CEACAM5
90 sigmoid neoplasm 10.2 KRT7 CEACAM5
91 pleomorphic adenoma 10.2 VIM MUC1 KRT7
92 microcystic adenoma 10.2 SERPINA3 MUC1
93 angiosarcoma 10.2 VIM MUC1 KRT7
94 acral lentiginous melanoma 10.2 VIM MUC1
95 malignant syringoma 10.2 KRT7 CEACAM5
96 oncocytoma 10.2 VIM MUC1 KRT7
97 mucinous stomach adenocarcinoma 10.2 NF2 KRT7
98 adenoid basal cell carcinoma 10.2 KRT7 CEACAM5
99 transverse colon cancer 10.2 KRT7 CEACAM5
100 appendiceal neoplasm 10.2 KRT7 CEACAM5
101 squamous cell bile duct carcinoma 10.2 KRT7 CEACAM5
102 appendix adenocarcinoma 10.2 KRT7 CEACAM5
103 gingival hypertrophy 10.2 VIM SERPINA3
104 clear cell hidradenoma 10.2 KRT7 CEACAM5
105 hidrocystoma 10.2 KRT7 CEACAM5
106 pericardium cancer 10.2 KRT7 CEACAM5
107 chondrosarcoma 10.2 VIM SERPINA3 MUC1
108 eccrine sweat gland cancer 10.2 KRT7 CEACAM5
109 warthin tumor 10.2 KRT7 CEACAM5
110 ovarian mucinous neoplasm 10.2 KRT7 CEACAM5
111 eccrine acrospiroma 10.2 KRT7 CEACAM5
112 eccrine sweat gland neoplasm 10.2 KRT7 CEACAM5
113 epithelioid leiomyosarcoma 10.2 VIM SERPINA3 MUC1
114 leiomyosarcoma 10.2 VIM SERPINA3 MUC1
115 sarcomatous intrahepatic cholangiocarcinoma 10.2 KRT7 CEACAM5
116 adenomatoid tumor 10.2 VIM TRAF7 KRT7
117 pleomorphic liposarcoma 10.2 VIM SERPINA3 MUC1
118 eccrine papillary adenocarcinoma 10.2 KRT7 CEACAM5
119 heart cancer 10.2 SERPINA3 KRT7
120 cutaneous adenocystic carcinoma 10.2 KRT7 CEACAM5
121 hemangiopericytoma, malignant 10.2 VIM SERPINA3 MUC1
122 chromophobe renal cell carcinoma 10.2 VIM MUC1 KRT7
123 nasal cavity olfactory neuroblastoma 10.2 KRT7 CEACAM5
124 benign giant cell tumor 10.2 VIM SERPINA3 MUC1
125 pancreatoblastoma 10.2 SERPINA3 MUC1
126 lipoadenoma 10.2 SERPINA3 MUC1 KRT7
127 malignant fibrous histiocytoma 10.2 VIM SERPINA3 MUC1
128 apocrine adenocarcinoma 10.2 SERPINA3 MUC1 KRT7
129 lymphoepithelioma-like carcinoma 10.2 MUC1 KRT7
130 anaplastic ependymoma 10.2 VIM NF2 MUC1
131 urethral benign neoplasm 10.2 KRT7 CEACAM5
132 apocrine sweat gland neoplasm 10.2 KRT7 CEACAM5
133 optic nerve glioma 10.2 VIM NF2 MUC1
134 breast benign neoplasm 10.2 SERPINA3 MUC1 KRT7
135 duodenum adenocarcinoma 10.2 KRT7 CEACAM5
136 bile duct cysts 10.2 KRT7 CEACAM5
137 well-differentiated liposarcoma 10.2 SERPINA3 MUC1 KRT7
138 squamous papillomatosis 10.2 KRT7 CEACAM5
139 benign ependymoma 10.2 VIM NF2 MUC1
140 mediastinal cancer 10.2 KRT7 CEACAM5
141 xanthogranulomatous cholecystitis 10.2 SERPINA3 CEACAM5
142 pre-malignant neoplasm 10.2 SERPINA3 MUC1 KRT7
143 clear cell basal cell carcinoma 10.2 KRT7 CEACAM5
144 fibroma 10.2 VIM SERPINA3 KRT7
145 malignant spiradenoma 10.1 KRT7 CEACAM5
146 esophageal adenosquamous carcinoma 10.1 KRT7 CEACAM5
147 neurofibroma 10.1 VIM NF2 MUC1
148 chordoid glioma 10.1 NF2 MUC1 KRT7
149 congenital fibrosarcoma 10.1 VIM SERPINA3
150 ovarian germ cell cancer 10.1 KRT7 CEACAM5
151 intraneural perineurioma 10.1 TRAF7 NF2 MUC1
152 sarcomatoid mesothelioma 10.1 VIM MUC1
153 frontal convexity meningioma 10.1 TRAF7 NF2 KLF4
154 pancreatic foamy gland adenocarcinoma 10.1 MUC1 KRT7 CEACAM5
155 urinary bladder villous adenoma 10.1 MUC1 KRT7 CEACAM5
156 mucinous intrahepatic cholangiocarcinoma 10.1 MUC1 KRT7 CEACAM5
157 cholangiocarcinoma 10.1 MUC1 KRT7 CEACAM5
158 bile duct cystadenocarcinoma 10.1 MUC1 KRT7 CEACAM5
159 krukenberg carcinoma 10.1 MUC1 KRT7 CEACAM5
160 biliary papillomatosis 10.1 MUC1 KRT7 CEACAM5
161 colonic lymphangioma 10.1 MUC1 KRT7 CEACAM5
162 bile duct mucoepidermoid carcinoma 10.1 MUC1 KRT7 CEACAM5
163 biliary tract benign neoplasm 10.1 MUC1 KRT7 CEACAM5
164 pancreatic mucinous cystadenoma 10.1 MUC1 KRT7 CEACAM5
165 linitis plastica 10.1 MUC1 KRT7 CEACAM5
166 appendix disease 10.1 MUC1 KRT7 CEACAM5
167 gastric diffuse adenocarcinoma 10.1 MUC1 KRT7 CEACAM5
168 appendix cancer 10.1 MUC1 KRT7 CEACAM5
169 borst-jadassohn intraepidermal carcinoma 10.1 KRT7 CEACAM5
170 benign peritoneal mesothelioma 10.1 MUC1 KRT7 CEACAM5
171 ovarian benign neoplasm 10.1 MUC1 KRT7 CEACAM5
172 gastrointestinal carcinoma 10.1 MUC1 CEACAM7 CEACAM5
173 duodenum cancer 10.1 MUC1 KRT7 CEACAM5
174 duodenum disease 10.1 MUC1 KRT7 CEACAM5
175 pseudomyxoma peritonei 10.1 MUC1 KRT7 CEACAM5
176 vulvar disease 10.1 KRT7 CEACAM5
177 polycystic liver disease 1 with or without kidney cysts 10.1 MUC1 KRT7 CEACAM5
178 tubular adenocarcinoma 10.1 MUC1 KRT7 CEACAM5
179 benign teratoma 10.1 MUC1 KRT7 CEACAM5
180 thymic carcinoma 10.1 MUC1 KRT7 CEACAM5
181 small intestine cancer 10.1 MUC1 KRT7 CEACAM5
182 adenoid squamous cell carcinoma 10.1 VIM KRT7 CEACAM5
183 ampulla of vater cancer 10.1 MUC1 KRT7 CEACAM5
184 papillary adenoma 10.1 VIM KRT7 CEACAM5
185 cervical adenocarcinoma 10.1 KRT7 CEACAM7 CEACAM5
186 klatskin's tumor 10.1 KRT7 CEACAM5
187 pancreatic ductal carcinoma 10.1 MUC1 KRT7 KLF4 CEACAM7
188 endocervical carcinoma 10.1 VIM KRT7 CEACAM5
189 endodermal sinus tumor 10.1 VIM KRT7 CEACAM5
190 large cell carcinoma 10.1 MUC1 KRT7 CEACAM5
191 neuroendocrine carcinoma 10.0 MUC1 KRT7 CEACAM5
192 colorectal adenocarcinoma 10.0 MUC1 KRT7 CEACAM5
193 benign mesothelioma 10.0 TRAF7 KRT7 CEACAM5
194 epithelioid malignant peripheral nerve sheath tumor 10.0 SMARCB1 MUC1
195 lymphangioma 10.0 VIM SERPINA3 CEACAM5
196 ovarian cystadenocarcinoma 10.0 SERPINA3 MUC1 CEACAM5
197 ovarian mucinous cystadenocarcinoma 10.0 VIM SERPINA3 CEACAM5
198 otitis media 10.0
199 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
200 visual epilepsy 10.0
201 adenocarcinoma 10.0
202 seizure disorder 10.0
203 liver sarcoma 10.0 SERPINA3 KRT7 CEACAM5
204 ovarian mucinous adenocarcinoma 10.0 SERPINA3 KRT7 CEACAM5
205 cecal disease 10.0 SERPINA3 KRT7 CEACAM5
206 sweat gland disease 10.0 SERPINA3 KRT7 CEACAM5
207 mixed cell type cancer 10.0 SERPINA3 KRT7 CEACAM5
208 tonsil cancer 10.0 SERPINA3 KRT7 CEACAM5
209 reproductive organ benign neoplasm 10.0 SERPINA3 KRT7 CEACAM5
210 ovarian serous cystadenocarcinoma 10.0 SERPINA3 MUC1 CEACAM5
211 proliferative fasciitis 10.0 SMARCB1 SERPINA3
212 intestinal obstruction 10.0 SERPINA3 KRT7 CEACAM5
213 adenosarcoma 10.0 VIM SERPINA3
214 cerebrovascular benign neoplasm 9.9 SMARCB1 KRT7
215 ovarian small cell carcinoma 9.9 SMARCB1 MUC1
216 ependymoblastoma 9.9 VIM SMARCB1
217 monosomy 22 9.9 SMARCB1 NF2
218 peritoneum cancer 9.9 NF2 KRT7 CEACAM5
219 gastrointestinal system benign neoplasm 9.9 SERPINA3 KRT7 CEACAM5
220 bile duct adenocarcinoma 9.9 SERPINA3 KRT7 CEACAM5
221 chordoid meningioma 9.9 VIM TRAF7 NF2 MUC1
222 mature teratoma 9.9 KRT7 CEACAM5
223 bile duct disease 9.9 SERPINA3 KRT7 CEACAM5
224 gallbladder disease 9.9 SERPINA3 KRT7 CEACAM5
225 adenoid cystic carcinoma 9.9 VIM SERPINA3 MUC1 KRT7
226 biliary tract disease 9.9 SERPINA3 KRT7 CEACAM5
227 optic nerve sheath meningioma 9.9 SMARCB1 NF2
228 nodular hidradenoma 9.9 VIM MUC1 KRT7 CEACAM5
229 hidradenoma 9.9 VIM MUC1 KRT7 CEACAM5
230 eccrine porocarcinoma 9.9 VIM MUC1 KRT7 CEACAM5
231 schwannomatosis 1 9.9 SMARCB1 NF2
232 syringoma 9.9 VIM MUC1 KRT7 CEACAM5
233 sex cord-gonadal stromal tumor 9.9 VIM MUC1 KRT7 CEACAM5
234 endocervical adenocarcinoma 9.9 VIM MUC1 KRT7 CEACAM5
235 rhabdoid tumor predisposition syndrome 1 9.9 VIM SMARCB1 MUC1
236 papillary adenocarcinoma 9.9 VIM MUC1 KRT7 CEACAM5
237 mucinous adenocarcinoma 9.9 VIM MUC1 KRT7 CEACAM5
238 carcinosarcoma 9.9 VIM MUC1 KRT7 CEACAM5
239 myoepithelioma 9.9 VIM SMARCB1 MUC1
240 optic nerve neoplasm 9.9 SMARCB1 NF2
241 paget disease, extramammary 9.9 MUC1 KRT7 CEACAM7 CEACAM5
242 atypical teratoid rhabdoid tumor 9.9 VIM SMARCB1 MUC1
243 cell type benign neoplasm 9.9 SERPINA3 KRT7 CEACAM5
244 papilloma of choroid plexus 9.9 SMARCB1 MUC1 KRT7
245 angiomatous meningioma 9.9 TRAF7 SMARCE1 NF2
246 pleural disease 9.9 SERPINA3 NF2 CEACAM5
247 central epithelioid sarcoma 9.8 VIM SMARCB1 KRT7
248 vulvar proximal-type epithelioid sarcoma 9.8 VIM SMARCB1 KRT7
249 neurofibromatosis, type ii 9.8
250 migraine with or without aura 1 9.8
251 moyamoya disease 1 9.8
252 glioblastoma multiforme 9.8
253 astrocytoma 9.8
254 grade iii astrocytoma 9.8
255 adenoma 9.8
256 parasagittal meningioma 9.8
257 tuberculum sellae meningioma 9.8
258 neurofibromatosis 9.8
259 exophthalmos 9.8
260 48,xyyy 9.8
261 glioma 9.8
262 glial tumor 9.8
263 epithelial-myoepithelial carcinoma 9.8 VIM SMARCB1 KRT7
264 chondroid chordoma 9.8 VIM SERPINA3 MUC1 CEACAM5
265 skull base cancer 9.8 TRAF7 SERPINA3 NF2 KLF4
266 skull base meningioma 9.8 TRAF7 SERPINA3 NF2 KLF4
267 myxoid chondrosarcoma 9.8 SMARCB1 MUC1
268 cranial nerve neoplasm 9.8 SMARCB1 NF2
269 corpus callosum lipoma 9.8 SMARCB1 NF2
270 hepatoid adenocarcinoma 9.8 SERPINA3 MUC1 KRT7 CEACAM5
271 thoracic benign neoplasm 9.8 SERPINA3 MUC1 KRT7 CEACAM5
272 cerebral hemisphere lipoma 9.8 SMARCB1 NF2
273 cystadenoma 9.8 SERPINA3 MUC1 KRT7 CEACAM5
274 mucoepidermoid carcinoma 9.8 SERPINA3 MUC1 KRT7 CEACAM5
275 peritoneal mesothelioma 9.8 VIM NF2 MUC1 CEACAM5
276 ovary adenocarcinoma 9.8 SERPINA3 MUC1 KRT7 CEACAM5
277 ovary epithelial cancer 9.8 SERPINA3 MUC1 KRT7 CEACAM5
278 malignant ovarian surface epithelial-stromal neoplasm 9.8 SERPINA3 MUC1 KRT7 CEACAM5
279 small cell cancer of the lung 9.8 PSG2 KRT7 CEACAM7 CEACAM5
280 synovium cancer 9.7 SMARCB1 SERPINA3 KRT7
281 schwannoma of twelfth cranial nerve 9.7 SMARCB1 NF2 KRT7
282 cerebrum cancer 9.7 SMARCB1 NF2
283 hypoglossal nerve disease 9.7 SMARCB1 NF2 KRT7
284 cerebral ventricle cancer 9.7 SMARCB1 NF2
285 transitional meningioma 9.7 TRAF7 SMARCE1 NF2 MUC1
286 keratinizing squamous cell carcinoma 9.7 SMARCB1 KRT7 CEACAM5
287 medulloepithelioma 9.7 VIM SMARCB1 MUC1 KRT7
288 myoepithelial carcinoma 9.7 VIM SMARCB1 MUC1 KRT7
289 mesenchymal chondrosarcoma 9.7 VIM SMARCB1 MUC1 KRT7
290 collecting duct carcinoma 9.7 VIM SMARCB1 MUC1 KRT7
291 epithelioid sarcoma 9.7 VIM SMARCB1 MUC1 KRT7
292 gastric adenocarcinoma 9.6 MUC1 KRT7 KLF4 CEACAM7 CEACAM5
293 spindle cell sarcoma 9.6 VIM SERPINA3 NF2 MUC1 KRT7
294 ureter, cancer of 9.6 KRT7 CEACAM5
295 cystadenocarcinoma 9.6 VIM SERPINA3 MUC1 KRT7 CEACAM5
296 adenosquamous carcinoma 9.6 SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
297 myxopapillary ependymoma 9.6 VIM SMARCB1 NF2 MUC1
298 mesothelioma, malignant 9.5 VIM NF2 MUC1 KRT7 CEACAM5
299 fibrous meningioma 9.5 VIM TRAF7 NF2 MUC1 EGFL6
300 renal cell carcinoma, papillary, 1 9.5 SMARCB1 NF2 KRT7
301 coffin-siris syndrome 3 9.5 SMARCE1 SMARCB1
302 rhabdoid meningioma 9.5 VIM TRAF7 SMARCB1 NF2
303 lung cancer susceptibility 3 9.5 SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
304 neurilemmomatosis 9.5 SMARCE1 SMARCB1 NF2
305 central nervous system cancer 9.5 SMARCB1 SERPINA3 NF2
306 benign meningioma 9.5 TRAF7 SMARCE1 NF2 EGFL6
307 neuroma 9.5 SMARCB1 SERPINA3 NF2 MUC1
308 teratoma 9.4 VIM SMARCB1 KRT7 CEACAM5
309 supratentorial cancer 9.4 SMARCB1 NF2
310 sweat gland benign neoplasm 9.4 SMARCB1 SERPINA3 KRT7 CEACAM5
311 mucinous cystadenocarcinoma 9.4 VIM SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
312 chordoma 9.4 VIM SMARCB1 SERPINA3 MUC1 KRT7
313 sarcoma, synovial 9.4 VIM SMARCB1 SERPINA3 MUC1 KRT7
314 malignant peripheral nerve sheath tumor 9.3 VIM SMARCB1 NF2 MUC1 KRT7
315 sarcoma 9.3 VIM SMARCB1 SERPINA3 NF2 MUC1
316 neurilemmoma 9.3 VIM SMARCB1 SERPINA3 NF2 MUC1
317 spinal canal and spinal cord meningioma 9.2 TRAF7 SMARCE1 SMARCB1 NF2
318 spinal cancer 9.2 TRAF7 SMARCE1 SMARCB1 NF2
319 peripheral nerve schwannoma 9.2 SMARCE1 SMARCB1 SERPINA3 NF2
320 clear cell meningioma 8.8 VIM TRAF7 SMARCE1 SMARCB1 NF2 MUC1

Graphical network of the top 20 diseases related to Secretory Meningioma:



Diseases related to Secretory Meningioma

Symptoms & Phenotypes for Secretory Meningioma

GenomeRNAi Phenotypes related to Secretory Meningioma according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

Drugs & Therapeutics for Secretory Meningioma

Drugs for Secretory Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 242, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3 Fibrin Tissue Adhesive Phase 4
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Antifibrinolytic Agents Phase 4
7
Cisatracurium Approved Phase 3 96946-41-7
8
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
10
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
11
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Donepezil Approved Phase 3 120014-06-4 3152
14
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Aminolevulinic acid Approved Phase 3 106-60-5 137
18
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Histamine Approved, Investigational Phase 3 51-45-6 774
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Antihypertensive Agents Phase 3
24 Progestins Phase 3
25 Cholinesterase Inhibitors Phase 3
26 Cholinergic Agents Phase 3
27 Analgesics Phase 3
28 Liver Extracts Phase 3
29 Cola Phase 3
30 Emetics Phase 3
31 Narcotics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics, General Phase 3
34 Anesthetics, Intravenous Phase 3
35 Anesthetics Phase 2, Phase 3
36 Gastrointestinal Agents Phase 3
37 Neurotransmitter Agents Phase 3
38 Central Nervous System Stimulants Phase 3
39 Dermatologic Agents Phase 3
40 Dopamine Agents Phase 3
41 Dexmethylphenidate Hydrochloride Phase 3
42 Histamine Antagonists Phase 3
43 Anti-Allergic Agents Phase 3
44
Histamine Phosphate Phase 3 51-74-1 65513
45 Histamine H1 Antagonists Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
48
Hydroxyurea Approved Phase 2 127-07-1 3657
49
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
50
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
51
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
52
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
53
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
54
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
55
Levetiracetam Approved Phase 2 102767-28-2 441341
56
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
57
Carmustine Approved, Investigational Phase 2 154-93-8 2578
58
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
59
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
60
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
61
Verapamil Approved Phase 2 52-53-9 2520
62
Mesna Approved, Investigational Phase 2 3375-50-6 598
63
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
64
carbamide peroxide Approved Phase 2 124-43-6
65
Pembrolizumab Approved Phase 2 1374853-91-4
66
nivolumab Approved Phase 2 946414-94-4
67
Ipilimumab Approved Phase 2 477202-00-9
68
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
69
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
70
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
71
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
72
Bevacizumab Approved, Investigational Phase 2 216974-75-3
73
Pasireotide Approved Phase 2 396091-73-9 9941444
74
Trioxsalen Approved Phase 2 3902-71-4 5585
75
Ifosfamide Approved Phase 2 3778-73-2 3690
76
Vatalanib Investigational Phase 2 212141-54-3 151194
77 Molgramostim Investigational Phase 2 99283-10-0
78
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
79 Imatinib Mesylate Phase 2 220127-57-1 123596
80 Anticonvulsants Phase 2
81 Cytochrome P-450 Enzyme Inhibitors Phase 2
82 Cytochrome P-450 CYP3A Inhibitors Phase 2
83 Trace Elements Phase 1, Phase 2
84 Copper Supplement Phase 1, Phase 2
85 Nutrients Phase 1, Phase 2
86 Micronutrients Phase 1, Phase 2
87 Interleukin-2 Phase 2
88 Psychotropic Drugs Phase 2
89 Anti-Anxiety Agents Phase 2
90 Calcium, Dietary Phase 2
91 calcium channel blockers Phase 2
92
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
93 Anti-HIV Agents Phase 2
94 Anti-Retroviral Agents Phase 2
95 Semaxinib Phase 1, Phase 2
96 Tubulin Modulators Phase 2
97 Antimitotic Agents Phase 2
98 Ginkgo Phase 2
99 Interferon-alpha Phase 2
100 interferons Phase 2
101 Interferon alpha-2 Phase 2
102 Iron-Dextran Complex Phase 2
103 Vaccines Phase 2
104 Albumin-Bound Paclitaxel Phase 2
105 Antirheumatic Agents Phase 2
106 Anti-Arrhythmia Agents Phase 2
107 Vasodilator Agents Phase 2
108 Mitogens Phase 2
109 Endothelial Growth Factors Phase 2
110 Immunoglobulin G Phase 2
111 Protein Kinase Inhibitors Phase 1, Phase 2
112 Immunoglobulins Phase 2
113 Antibodies Phase 2
114 Antibodies, Monoclonal Phase 2
115 Immunoglobulins, Intravenous Phase 2
116 Etoposide phosphate Phase 1, Phase 2
117 Amino-acid, glucose, and electrolyte solution Phase 2
118 Parenteral Nutrition Solutions Phase 2
119 Hormone Antagonists Phase 2
120 Hormones Phase 2
121 Alkylating Agents Phase 2
122 Antineoplastic Agents, Immunological Phase 2
123 Immunologic Factors Phase 2
124 Immunosuppressive Agents Phase 2
125 Angiogenesis Inhibitors Phase 2
126 Dihematoporphyrin Ether Phase 2
127 Photosensitizing Agents Phase 2
128
Isophosphamide mustard Phase 2 0
129 Hematoporphyrin Derivative Phase 2
130 Ether Phase 2
131
Calcium Nutraceutical Phase 2 7440-70-2 271
132
Verteporfin Approved, Investigational Phase 1 129497-78-5
133
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
134
Busulfan Approved, Investigational Phase 1 55-98-1 2478
135
Lenalidomide Approved Phase 1 191732-72-6 216326
136
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
137
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
138
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
139
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
140
Vincristine Approved, Investigational Phase 1 57-22-7, 2068-78-2 5978
141
Iodine Approved, Investigational Phase 1 7553-56-2 807
142
Pioglitazone Approved, Investigational Phase 1 111025-46-8 4829
143
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
144
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
145
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
146
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
147
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
148
Cobalt Approved, Experimental Phase 1 7440-48-4 104729
149
Trametinib Approved Phase 1 871700-17-3 11707110
150
Lenograstim Approved, Investigational Phase 1 135968-09-1
151
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
152
Gemcitabine Approved Phase 1 95058-81-4 60750
153
Piperazine Approved, Vet_approved Phase 1 110-85-0 4837
154
Palbociclib Approved, Investigational Phase 1 571190-30-2 5005498 11431660 5330286
155
Mebendazole Approved, Vet_approved Phase 1 31431-39-7 4030
156
Topotecan Approved, Investigational Phase 1 123948-87-8, 119413-54-6 60700